Exclusive special offer and discount title banner vector image

CAR-T THERAPY PIPELINE INSIGHT 2024

SCOPE OF THE REPORT

Car-T Therapy Pipeline Therapeutic Assessment: Active Products (Evaluation by Route of Administration, Evaluation by Stage and Route of Administration, Evaluation by Therapy Area, Evaluation by Stage and Therapy Area, Evaluation by Product Type, Evaluation by Stage and Product Type)

REQUEST CUSTOMIZATION

MARKET OVERVIEW

CAR-T therapy, or chimeric antigen receptor T-cell therapy, is a groundbreaking advancement in the field of immunotherapy, particularly in the treatment of hematologic malignancies such as leukemia and lymphoma. This highly specialized procedure involves the genetic modification of a patient’s T cells to express receptors specifically designed to recognize and attack cancer cells. 

The process begins with the collection of T cells from the patient’s blood through leukapheresis. These cells are then altered in a laboratory setting to produce chimeric antigen receptors (CARs) on their surface. The engineered T cells are subsequently expanded in number before being infused back into the patient’s body to target and eliminate cancer cells.

CAR-T Therapy

Read our latest blog on the CAR-T Therapy Market

GROWTH ENABLERS

Key enablers of the global CAR-T therapy market growth: 

  • Expanding range of targets and indications
  • Surge in clinical and preclinical studies yielding positive results
  • Growing collaborations and acquisitions in the market
    • The field of CAR-T cell therapy has seen a surge of new companies entering through collaborations and joint ventures. These partnerships drive the market by fostering opportunities where the synergy of diverse ideas and technical skills can be leveraged. 
    • Acquisitions play a crucial role in the CAR-T therapy landscape, allowing companies to diversify their portfolios and address a broader spectrum of medical conditions. By merging resources and expertise, companies can expand their capabilities and offer more comprehensive solutions in the field of CAR-T therapy.
    • Collaborations and acquisitions also facilitate access to global markets and streamline regulatory approvals across different regions, ultimately increasing patient access to CAR-T therapy.

GROWTH RESTRAINTS

Key growth restraining factors of the global CAR-T therapy market:

  • Optimizing dosing and addressing toxicity concerns 
  • Ensuring scalability and cost-effectiveness for accessibility and affordability
    • The therapy’s high upfront cost poses a substantial barrier. The complex process of mass-producing CAR-T cell products, combined with the need for synchronized clinical data, setup, and developmental costs, contributes to these financial challenges.
    • The financial burden associated with CAR-T therapy often limits patient access, as the high costs make it unaffordable for many individuals. This limitation not only affects patient outcomes but also impacts market demand.
    • High treatment costs and financial barriers create a challenging market environment for CAR-T therapy, especially when more cost-effective alternatives are available. The competition from these alternatives can further impede the market expansion of CAR-T therapy.
  • Overcoming technological barriers

To Know More About This Report, Request a Free Sample Copy

CAR-T Therapy | Overview

  • Introduction
  • Structure of CAR-T cells
    • CAR-T cells have become a promising alternative to traditional treatments such as radiation, chemotherapy, and immunotherapy for malignant cancers. CARs are specially engineered receptors that modify T cell receptors (TCRs) and are composed of four primary components: target antigen-binding domain, spacer region, transmembrane domain, and intracellular signaling domains.
    • These synthetic components are incorporated into viral vectors and subsequently introduced into T cells. This modification redirects the immune response specifically towards malignant cells, enhancing the body’s ability to target and destroy cancer cells effectively.
  • CARS generations
  • Advantages of CAR-T cells
    • Tumor cells often lack the costimulatory ligands required for effective T-cell activation, which limits the efficacy of first-generation CARs. Prolonged in vitro expansion of T cells can further decrease receptors for these ligands, compounding the problem.
    • To overcome this, second-generation CARs have been developed with additional stimulatory domains from costimulatory molecules like CD28, OX40, 4-1BB, DAP10, ICOS, and Lck. These domains provide both signal-1 and signal-2 upon antigen engagement, enhancing T-cell activation and preventing apoptosis due to insufficient signaling. Studies show that second-generation CARs improve T cell function compared to first-generation CARs.
    • Third-generation CARs incorporate three or more stimulatory domains (e.g., CD3z-CD28-41BB or CD3z-CD28-OX40) to boost potency. However, they have shown mixed results regarding costimulation potential, and there are concerns about adverse events, indicating the need for careful development in this area.
  • Adverse events with CAR-T cell therapy
  • Limitations of existing technologies for CAR-T cells

MAJOR PLAYERS

Major players in the global CAR-T therapy market:

  • Carsgen Therapeutics
  • Gilead Sciences
  • Novartis AG
  • Tessa Therapeutics
  • Janssen Pharmaceuticals
  • Bristol Myers Squibb
  • JW Therapeutics

Novartis AG is an international manufacturer of healthcare products, operating through two segments: Innovative Medicines and Sandoz. The company’s product portfolio includes surgical instruments, ophthalmic pharmaceuticals, vision care products, generic medicines and biosimilars. It provides products for cancer, cardiometabolic, and cell and gene therapy. It offers its products under AIR OPTIX, Alcon, Sandoz, Votrient, DAILIES, FreshLook, Clear Care, and Lucentis brands. Novartis operates across Asia-Pacific, Europe, the Americas, and the Middle East and Africa. The company is headquartered in Basel, Switzerland.

CTL119 (CD19 CAR) is a humanized CD19 CAR therapy currently in Phase II clinical trials for treating Acute Lymphoid Leukemia. This therapy is being developed by Novartis in collaboration with the University of Pennsylvania. The production of CTL119 involves extracting some of the patient’s T cells and reprogramming them at Penn’s Clinical Cell and Vaccine Production Facility using a gene transfer technique. This process equips the T cells with a chimeric antigen receptor (CAR), an antibody-like protein that specifically targets the CD19 protein on the surface of cancerous B cells. Once these engineered “hunter” cells are infused back into the patient’s body, they proliferate and are believed to effectively target and destroy the cancer cells.

TABLE OF CONTENTS

  1. INTRODUCTION TO THE REPORT
  2. CAR-T THERAPY: SUMMARY
  3. OVERVIEW
    1. INTRODUCTION
    2. STRUCTURE OF CAR-T CELLS
    3. CARS GENERATIONS
    4. ADVANTAGES OF CAR-T CELLS
    5. ADVERSE EVENTS WITH CAR-T CELL THERAPY
    6. LIMITATIONS OF EXISTING TECHNOLOGIES FOR CAR-T CELLS
  4. MARKET DYNAMICS
    1. KEY DRIVERS
      1. EXPANDING RANGE OF TARGETS AND INDICATIONS
      2. SURGE IN CLINICAL AND PRECLINICAL STUDIES YIELDING POSITIVE RESULTS
      3. GROWING COLLABORATIONS AND ACQUISITIONS 
    2. KEY RESTRAINTS
      1. OPTIMIZING DOSING AND ADDRESSING TOXICITY CONCERNS 
      2. ENSURING SCALABILITY AND COST-EFFECTIVENESS FOR ACCESSIBILITY AND AFFORDABILITY
      3. OVERCOMING TECHNOLOGICAL BARRIERS
  5. PIPELINE THERAPEUTICS
    1. CURRENT PIPELINE OVERVIEW
    2. COMPARATIVE ANALYSIS: PRODUCTS IN VARIOUS PHASES
  6. THERAPEUTIC ASSESSMENT: ACTIVE PRODUCTS
    1. EVALUATION BY ROUTE OF ADMINISTRATION
    2. EVALUATION BY STAGE AND ROUTE OF ADMINISTRATION
    3. EVALUATION BY THERAPY AREA
    4. EVALUATION BY STAGE AND THERAPY AREA
    5. EVALUATION BY PRODUCT TYPE
    6. EVALUATION BY STAGE AND PRODUCT TYPE
  7. LATE-STAGE PRODUCTS (REGISTERED)
    1. COMPARATIVE ANALYSIS
      1. CNCT-19: CASI PHARMACEUTICALS/JUVENTAS CELL THERAPY
        1. PRODUCT DESCRIPTION
        2. RESEARCH AND DEVELOPMENT
        3. SAFETY AND EFFICACY
        4. PRODUCT DEVELOPMENTAL ACTIVITIES
      2. CT053: CARSGEN THERAPEUTICS
        1. PRODUCT DESCRIPTION
        2. RESEARCH AND DEVELOPMENT
        3. SAFETY AND EFFICACY
        4. PRODUCT DEVELOPMENTAL ACTIVITIES
  8. MID-STAGE PRODUCTS (PHASE II)
    1. COMPARATIVE ANALYSIS
    2. JWCAR029: JW THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
    3. KTE-X19: JW THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
    4. CILTACABTAGENE AUTOLEUCEL: JANSSEN PHARMACEUTICALS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT AND DEVELOPMENTAL ACTIVITIES
    5. DESCARTES 11: CARTESIAN THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    6. CTL119: NOVARTIS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT AND DEVELOPMENTAL ACTIVITIES
    7. TT11: TESSA THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
      4. PRODUCT DEVELOPMENTAL ACTIVITIES
    8. CD19+CD22 CAR-T CELL SEQUENTIAL THERAPY: WUHAN BIO RAID BIOTECHNOLOGY
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
    9. MB-CART2019.1: MILTENYI BIOMEDICINE
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
      4. PRODUCT DEVELOPMENTAL ACTIVITIES
    10. JCAR017: BRISTOL-MYERS SQUIBB
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
      4. PRODUCT DEVELOPMENTAL ACTIVITIES
    11. DESCARTES-08: CARTESIAN THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
    12. PCAR-19B: CHONGQING PRECISION BIOTECH
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    13. ALLO-501A: ALLOGENE THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
      4. PRODUCT DEVELOPMENTAL ACTIVITIES
    14. HUMAN CD19 TARGETED T-CELLS INJECTION THERAPY: HRAIN BIOTECHNOLOGY
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    15. UCART19: SERVIER
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
      4. PRODUCT AND DEVELOPMENTAL ACTIVITIES
    16. CART-DDBCMA: ARCELLX
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
      4. PRODUCT DEVELOPMENTAL ACTIVITIES
    17. CD22 CAR T: CARGO THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
      4. PRODUCT AND DEVELOPMENTAL ACTIVITIES
    18. GC007G: GRACELL BIO
      1. PRODUCT DESCRIPTION
    19. CD7 CAR-T CELLS INFUSION: PERSONGEN BIOTHERAPEUTICS (SUZHOU)
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
    20. KITE-222: KITE PHARMA
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
    21. AXICABTAGENE CILOLEUCEL: KITE PHARMA
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    22. BCMA CHIMERIC ANTIGEN RECEPTOR THERAPY: HRAIN BIOTECHNOLOGY
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    23. IMN-003A: IMMUNEEL
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
  9. EARLY-STAGE PRODUCTS (PHASE I/II)
    1. COMPARATIVE ANALYSIS
    2. AUTO4: AUTOLUS LIMITED
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
    3. AUTO3: AUTOLUS LIMITED
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
    4. IM19 CAR-T: BEIJING IMMUNOCHINA MEDICAL SCIENCE AND TECHNOLOGY
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    5. CT032: CARSGEN THERAPEUTICS CO., LTD
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    6. ORVACABTAGENE AUTOLEUCEL: CELGENE
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
    7. BCMA CAR-T CELLS: CHONGQING PRECISION BIOTECH
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    8. CD123 CAR-T CELLS: CHONGQING PRECISION BIOTECH
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    9. CD19 CAR-T CELLS: CHONGQING PRECISION BIOTECH
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    10. CIK-CAR.CD19: COIMMUNE, INC
      1. PRODUCT DESCRIPTION
      2. PRODUCT DEVELOPMENTAL ACTIVITIES
    11. MB-102: MUSTANG BIO
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
    12. AU101: AURORA BIOPHARMA
      1. PRODUCT DESCRIPTION
    13. ATA2271: ATARA BIOTHERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    14. AU105: AURORA BIOPHARMA
      1. PRODUCT DESCRIPTION
    15. AUTO1: AUTOLUS THERAPEUTICS LTD
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
      4. PRODUCT DEVELOPMENTAL ACTIVITIES
    16. CAR-T CELLS TARGETING CD19 AND CD22: YAKE BIOTECHNOLOGY
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    17. HUMNC2-CAR44 CAR-T CELLS: MINERVA BIOTECHNOLOGIES
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    18. CD19-CART: SHANGHAI GENECHEM
      1. PRODUCT DESCRIPTION
    19. MB-106 (CD20 CAR): MUSTANG BIO
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
    20. CTX110: CRISPR THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    21. WU-CART-007: WUGEN
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
      4. PRODUCT DEVELOPMENTAL ACTIVITIES
    22. GC012F: GRACELL BIOTECHNOLOGY SHANGHAI CO., LTD
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
      4. PRODUCT DEVELOPMENTAL ACTIVITIES
    23. C-CAR039: CELLULAR BIOMEDICINE GROUP LTD
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
    24. VOR33: VOR BIOPHARMA
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
    25. BBT369: 2SEVENTY BIO
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    26. UCART20X22: CELLECTIS S.A.
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    27. NXC 201: NEXCELLA
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENT ACTIVITIES
    28. IVS-3001: INVECTYS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENT ACTIVITIES
    29. IMPT 314: IMMPACT BIO
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENT ACTIVITIES
    30. CT120: IASO BIOTHERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENT ACTIVITIES
    31. CD22 CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY: YAKE BIOTECHNOLOGY
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    32. CD19 CAR-T CELL THERAPY: SHANGHAI UNICAR-THERAPY BIO-MEDICINE TECHNOLOGY
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
    33. CART22 THERAPY: NOVARTIS PHARMACEUTICALS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    34. KD-182 CAR T CELLS: NANJING KAEDI BIOTECH
      1. PRODUCT DESCRIPTION
    35. CRC01: CUROCELL
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
    36. CT041: CARSGEN THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
      4. PRODUCT DEVELOPMENTAL ACTIVITIES
    37. VCAR33: VOR BIOPHARMA
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENTAL STUDIES
    38. PBCAR0191: PRECISION BIOSCIENCES
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
      4. PRODUCT DEVELOPMENTAL ACTIVITIES
    39. HUMANIZED CD19 CAR-T CELLS: SHANGHAI UNICAR-THERAPY BIO-MEDICINE TECHNOLOGY
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    40. TBI-1501: TAKARA BIO
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    41. BNT211: BIONTECH
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
    42. MB-CART19.1: MILTENYI BIOMEDICINE
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
    43. MB-CART20.1: MILTENYI BIOMEDICINE
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
    44. CD-7 CAR-T MOLECULE: YAKE BIOTECHNOLOGY
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    45. KD-025 CAR T CELLS: NANJING KAEDI BIOTECH
      1. PRODUCT DESCRIPTION
    46. IM19 CAR-T: BEIJING IMMUNOCHINA MEDICAL SCIENCE AND TECHNOLOGY
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    47. IC9-CAR19 CELLS: BELLICUM PHARMACEUTICALS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    48. KYV-101: KYVERNA THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT AND DEVELOPMENTAL ACTIVITIES
    49. UCART22: CELLECTIS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
    50. HUMANIZED CD19 CAR-T CELLS: SHANGHAI UNICAR-THERAPY BIO-MEDICINE TECHNOLOGY
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    51. BOXR 1030: SOTIO BIOTECH INC
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
      4. PRODUCT DEVELOPMENTAL ACTIVITIES
    52. BEAM 201: BEAM THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
    53. AT101: ABCLON
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
  10. EARLY-STAGE PRODUCTS (PHASE I)
    1. COMPARATIVE ANALYSIS
    2. CT103A: NANJING IASO BIOTECHNOLOGY CO., LTD
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    3. AUTO1/22: AUTOLUS THERAPEUTICS
      1. PRODUCT DESCRIPTION
    4. IM21 CAR-T: BEIJING IMMUNOCHINA MEDICAL SCIENCE AND TECHNOLOGY
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    5. CAR-GPC3: CARSGEN THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    6. JCAR 020: CELGENE CORPORATION (A BMS COMPANY)
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    7. CD19 ARMORED CAR: CELGENE CORPORATION (A BMS COMPANY)
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    8. ALLO-715: ALLOGENE THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
      4. PRODUCT DEVELOPMENTAL ACTIVITIES
    9. PRGN-3005: PRECIGEN
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
      4. PRODUCT DEVELOPMENTAL ACTIVITIES
    10. XYF19 CAR-T CELLS: XI’AN YUFAN BIOTECHNOLOGY
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
    11. WZTL-002: WELLINGTON ZHAOTAI THERAPIES
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    12. TI-1007: TIMMUNE BIOTECH
      1. PRODUCT DESCRIPTION
    13. KUR-501: ATHENEX, INC
      1. PRODUCT DESCRIPTION
      2. PRODUCT DEVELOPMENTAL ACTIVITIES
    14. KUR-502: ATHENEX, INC
      1. PRODUCT DESCRIPTION
      2. SAFETY AND EFFICACY
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
    15. GC019F: GRACELL BIOTECHNOLOGY SHANGHAI CO., LTD
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
    16. MB-104: MUSTANG BIO
      1. PRODUCT DESCRIPTION
    17. MB-105: MUSTANG BIO
      1. PRODUCT DESCRIPTION
    18. MB-101: MUSTANG BIO
      1. PRODUCT DESCRIPTION
    19. CTX120: CRISPR THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    20. CTX130: CRISPR THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    21. BCMA TARGETED CAR-T CELLS: YAKE BIOTECHNOLOGY
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    22. CD19/BCMA TARGETED CAR-T CELLS: YAKE BIOTECHNOLOGY
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    23. CD4CAR: ICELL GENE THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
    24. FT-819: FATE THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    25. CB-010: CARIBOU BIOSCIENCES
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
      4. PRODUCT DEVELOPMENTAL ACTIVITIES
    26. P MUC1C ALLO1: POSEIDA THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
    27. P BCMA ALLO1: POSEIDA THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
      4. PRODUCT DEVELOPMENTAL ACTIVITIES
    28. TAA 06: PERSONGEN BIOTHERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    29. TAK 103: TAKEDA
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    30. STK-009 + SYNCAR-001: SYNTHEKINE
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
    31. P-CD19CD20-ALLO1: POSEIDA THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    32. NIB 101: NOILE-IMMUNE BIOTECH
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
    33. SC-DARIC33: 2SEVENTY BIO
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    34. IMPT 514: IMMPACT BIO
      1. PRODUCT DESCRIPTION
      2. PRODUCT DEVELOPMENT ACTIVITIES
    35. SYNKIR-110: VERISMO THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENT ACTIVITIES
    36. MT 027: T-MAXIMUM
      1. PRODUCT DESCRIPTION
      2. PRODUCT DEVELOPMENT ACTIVITIES
    37. CT125A: IASO BIOTHERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    38. RD133: IASO BIOTHERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    39. CT0181: CARSGEN THERAPEUTICS CO LTD
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    40. CT0590: CARSGEN THERAPEUTICS CO LTD
      1. PRODUCT DESCRIPTION
    41. CT048: CARSGEN THERAPEUTICS CO LTD
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    42. CT071: CARSGEN THERAPEUTICS CO LTD
      1. PRODUCT DESCRIPTION
    43. ACLX 001: ARCELLX
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
    44. ACLX 002: ARCELLX
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
    45. BMS-986393: BRISTOL MYERS SQUIBB
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
      4. PRODUCT AND DEVELOPMENTAL ACTIVITIES
    46. ANTI-BCMA CAR-T CELL: PROTHERAGEN
      1. PRODUCT DESCRIPTION
    47. P-PSMA-101: POSEIDA THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    48. NIB-102: TAKEDA / NOILE-IMMUNE BIOTECH
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
      4. PRODUCT AND DEVELOPMENTAL ACTIVITIES
    49. UCARTCS1: CELLECTIS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
    50. UCART123: CELLECTIS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
      4. PRODUCT DEVELOPMENTAL ACTIVITIES
    51. GPC3 TARGETING CAR-T CELLS: GUANGDONG ZHAOTAI INVIVO BIOMEDICINE
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    52. MB-103: MUSTANG BIO
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    53. TAK-940: TAKEDA
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    54. ADI-001: ADICET BIO
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    55. GC027: GRACELL BIO
      1. PRODUCT DESCRIPTION
      2. SAFETY AND EFFICACY
    56. IOMAB-ACT PROGRAM: ACTINIUM PHARMACEUTICALS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    57. ALL0-316: ALLOGENE THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
      4. PRODUCT DEVELOPMENTAL ACTIVITIES
    58. GPRC5D CAR T (MCARH 109): BRISTOL-MYERS SQUIBB
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
      4. PRODUCT AND DEVELOPMENTAL ACTIVITIES
    59. CLBR001 + SWI019: ABBVIE
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
    60. ANTI-CD20 CAR: CELLULAR BIOMEDICINE GROUP
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
    61. PRGN-3007: PRECIGEN, INC
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    62. CB-011: CARIBOU BIOSCIENCES
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT AND DEVELOPMENTAL ACTIVITIES
    63. KD-496: KAEDI
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
    64. AUTO8: AUTOLUS
      1. PRODUCT DESCRIPTION
    65. FOLLICLE STIMULATING HORMONE RECEPTOR T CELLS: ANIXA BIOSCIENCES
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    66. SENL_1904B: HEBEI SENLANG BIOTECHNOLOGY
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
    67. THISCART22: SUZHOU FUNDAMENTA THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    68. AIC100: AFFYIMMUNE THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT AND DEVELOPMENTAL ACTIVITIES
    69. PRGN-3006: PRECIGEN
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
      4. PRODUCT AND DEVELOPMENTAL ACTIVITIES
    70. CD79B CAR-T CELL THERAPY: YAKE BIOTECHNOLOGY
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    71. APRIL CAR-T CELLS CD79B: YAKE BIOTECHNOLOGY
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    72. LMP1 CAR-T CELLS: YAKE BIOTECHNOLOGY
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    73. NKG2D CAR-T CELL THERAPY: YAKE BIOTECHNOLOGY
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    74. TT11X (CD30-CAR EBVSTS): TESSA THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
    75. CD38 CAR T: SORRENTO THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
    76. BCMA-CART CELLS: PERSONGEN BIOTHERAPEUTICS (SUZHOU)
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    77. AUTOLOGOUS CHIMERIC ANTIGEN RECEPTOR T-CELL TRANSFUSING AGENT TARGETING CD22: PERSONGEN BIOTHERAPEUTICS (SUZHOU)
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    78. CAR-T-EGFRVIII: NOVARTIS PHARMACEUTICALS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    79. CART-BCMA: NOVARTIS PHARMACEUTICALS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    80. CART-MESO: NOVARTIS PHARMACEUTICALS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
    81. MURINE CD19 CAR T CELLS: YAKE BIOTECHNOLOGY
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    82. CS1 TARGETED CAR-T CELLS: YAKE BIOTECHNOLOGY
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    83. IL3 CAR-T CELLS: YAKE BIOTECHNOLOGY
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    84. CD70 CAR T- CELLS: YAKE BIOTECHNOLOGY
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    85. CD19 CAR T- CELLS: YAKE BIOTECHNOLOGY
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    86. ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELLS (KD-019 CAR-T): NANJING KAEDI BIOTECH
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    87. CD20 CAR T CELLS: MILTENYI BIOTEC
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    88. ANTI CD19 CAR: KECELLITICS BIOTECH COMPANY
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    89. CLL1B-CD33B COMPOUND CAR: ICELL GENE THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
      4. PRODUCT DEVELOPMENTAL ACTIVITIES
    90. CD19 CARVAC CELL THERAPY: ICELL GENE THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    91. BCMA-CD19 CCAR T CELLS THERAPY: ICELL GENE THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    92. ANTI-CD123-CART CELLS: HRAIN BIOTECHNOLOGY
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    93. ANTI- MESO CAR-T-CELLS: HRAIN BIOTECHNOLOGY
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    94. ANTI-CD19/BCMA BISPECIFIC CAR-T CELL THERAPY: HRAIN BIOTECHNOLOGY
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    95. TRIPLEX + CAR-TS: HELOCYTE
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    96. HER2/MESOTHELIN/LEWIS-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T CELL THERAPY: GUANGDONG ZHAOTAI INVIVO BIOMEDICINE
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    97. CD20/CD22 DUAL TARGETED CAR-T CELLS: YAKE BIOTECHNOLOGY
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    98. CC-97540: BRISTOL-MYERS SQUIBB
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    99. CT0180: CARSGEN THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    100. LMY-920: LUMINARY THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    101. BP2301: BRIGHTPATH THERAPEUTICS
      1. PRODUCT DESCRIPTION
    102. 2ND CAR-T/TCR-T: OXFORD BIOMEDICA
      1. PRODUCT DESCRIPTION
    103. CD19 2ND GENERATION CAR-T CELL THERAPY: PRECIGEN INC
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
  11. IND-STAGE PRODUCTS
    1. COMPARATIVE ANALYSIS
  12. PRECLINICAL-STAGE PRODUCTS
    1. COMPARATIVE ANALYSIS
  13. DISCOVERY-STAGE PRODUCTS
    1. COMPARATIVE ANALYSIS
  14. UNKNOWN-STAGE PRODUCTS
  15. INACTIVE PRODUCTS
    1. COMPARATIVE ANALYSIS
  16. STRATEGIC DEVELOPMENTS 
    1. MERGERS & ACQUISITIONS
    2. PARTNERSHIPS & AGREEMENTS
    3. INVESTMENTS
  17. UNMET NEEDS

LIST OF TABLES

TABLE 1: TOTAL ACTIVE PRODUCTS IN THE CAR-T THERAPY PIPELINE

TABLE 2: PRODUCTS IN VARIOUS PHASES

TABLE 3: EVALUATION BY ROUTE OF ADMINISTRATION

TABLE 4: EVALUATION BY THERAPY AREA

TABLE 5: EVALUATION BY PRODUCT TYPE

TABLE 6: LATE-STAGE PRODUCTS (REGISTERED)

TABLE 7: CLINICAL TRIALS DESCRIPTION: CNCT19

TABLE 8: GENERAL DESCRIPTION: CNCT19

TABLE 9: CLINICAL TRIALS DESCRIPTION: CT-053

TABLE 10: GENERAL DESCRIPTION: CT053

TABLE 11: MID-STAGE PRODUCTS (PHASE II)

TABLE 12: CLINICAL TRIALS DESCRIPTION: JWCAR029

TABLE 13: GENERAL DESCRIPTION: JWCAR029

TABLE 14: CLINICAL TRIALS DESCRIPTION: KTE-X19

TABLE 15: GENERAL DESCRIPTION: KTE-X19

TABLE 16: CLINICAL TRIALS DESCRIPTION: CILTACABTAGENE AUTOLEUCEL

TABLE 17: GENERAL DESCRIPTION: CILTACABTAGENE AUTOLEUCEL

TABLE 18: CLINICAL TRIALS DESCRIPTION: DESCARTES 11

TABLE 19: GENERAL DESCRIPTION: DESCARTES-11

TABLE 20: CLINICAL TRIALS DESCRIPTION: CTL 119

TABLE 21: GENERAL DESCRIPTION: CTL119

TABLE 22: CLINICAL TRIALS DESCRIPTION: TT 11

TABLE 23: GENERAL DESCRIPTION: TT11

TABLE 24: GENERAL DESCRIPTION: CD19+CD22 CAR-T CELL SEQUENTIAL THERAPY

TABLE 25: CLINICAL TRIALS DESCRIPTION: MB-CART2019.1

TABLE 26: GENERAL DESCRIPTION: MB-CART2019.1

TABLE 27: CLINICAL TRIALS DESCRIPTION: JCAR017

TABLE 28: GENERAL DESCRIPTION: JCAR 017

TABLE 29: CLINICAL TRIALS DESCRIPTION: DESCARTES-08

TABLE 30: GENERAL DESCRIPTION: DESCARTES-08

TABLE 31: CLINICAL TRIALS DESCRIPTION: PCAR-19B

TABLE 32: GENERAL DESCRIPTION: PCAR-19B

TABLE 33: CLINICAL TRIALS DESCRIPTION: ALLO-501A

TABLE 34: GENERAL DESCRIPTION: ALLO-501A

TABLE 35: CLINICAL TRIALS DESCRIPTION: HUMAN CD19 TARGETED T CELLS INJECTION

TABLE 36: GENERAL DESCRIPTION: HUMAN CD19 TARGETED T CELLS INJECTION

TABLE 37: CLINICAL TRIALS DESCRIPTION: UCART19

TABLE 38: GENERAL DESCRIPTION: UCART19

TABLE 39: CLINICAL TRIALS DESCRIPTION: CART-DDBCMA

TABLE 40: GENERAL DESCRIPTION: CART-DDBCMA

TABLE 41: CLINICAL TRIALS DESCRIPTION: CD22 CAR T

TABLE 42: GENERAL DESCRIPTION: CD22 CAR T

TABLE 43: GENERAL DESCRIPTION: GC007G

TABLE 44: CLINICAL TRIALS DESCRIPTION: CD7 CAR-T CELLS

TABLE 45: GENERAL DESCRIPTION: CD7 CAR-T CELLS INFUSION

TABLE 46: CLINICAL TRIALS DESCRIPTION: KITE-222

TABLE 47: GENERAL DESCRIPTION: KITE-222

TABLE 48: CLINICAL TRIALS DESCRIPTION: AXICABTAGENE CILOLEUCEL

TABLE 49: GENERAL DESCRIPTION: AXICABTAGENE CILOLEUCEL

TABLE 50: CLINICAL TRIALS DESCRIPTION: HUMAN BCMA TARGETED T-CELL INJECTION

TABLE 51: GENERAL DESCRIPTION: BCMA CHIMERIC ANTIGEN RECEPTOR THERAPY

TABLE 52: CLINICAL TRIALS DESCRIPTION: IMN-003A

TABLE 53: GENERAL DESCRIPTION: IMN-003A

TABLE 54: EARLY-STAGE PRODUCTS (PHASE I/II)

TABLE 55: CLINICAL TRIALS DESCRIPTION: AUTO4

TABLE 56: GENERAL DESCRIPTION: AUTO4

TABLE 57: CLINICAL TRIALS DESCRIPTION: AUTO3

TABLE 58: GENERAL DESCRIPTION: AUTO3

TABLE 59: CLINICAL TRIALS DESCRIPTION: IM19 CAR-T CELLS

TABLE 60: GENERAL DESCRIPTION: IM19 CAR-T

TABLE 61: CLINICAL TRIALS DESCRIPTION: CT032

TABLE 62: GENERAL DESCRIPTION: CT032

TABLE 63: CLINICAL TRIALS DESCRIPTION: ORVACABTAGENE AUTOLEUCEL

TABLE 64: GENERAL DESCRIPTION: ORVACABTAGENE AUTOLEUCEL

TABLE 65: CLINICAL TRIALS DESCRIPTION: BCMA CAR-T CELLS

TABLE 66: GENERAL DESCRIPTION: BCMA CAR-T CELLS

TABLE 67: CLINICAL TRIALS DESCRIPTION: CD123 CAR-T CELLS

TABLE 68: GENERAL DESCRIPTION: CD123 CAR-T CELLS

TABLE 69: CLINICAL TRIALS DESCRIPTION: CD19 CAR-T CELLS

TABLE 70: GENERAL DESCRIPTION: CD19 CAR-T CELLS

TABLE 71: GENERAL DESCRIPTION: CIK-CAR.CD19

TABLE 72: CLINICAL TRIALS DESCRIPTION: MB 102

TABLE 73: GENERAL DESCRIPTION: MB-102

TABLE 74: GENERAL DESCRIPTION: AU101

TABLE 75: CLINICAL TRIALS DESCRIPTION: ATA2271

TABLE 76: GENERAL DESCRIPTION: ATA2271

TABLE 77: GENERAL DESCRIPTION: AU105

TABLE 78: CLINICAL TRIALS DESCRIPTION: AUTO1

TABLE 79: GENERAL DESCRIPTION: AUTO1

TABLE 80: CLINICAL TRIALS DESCRIPTION: CAR-T CELLS TARGETING CD19 AND CD22

TABLE 81: GENERAL DESCRIPTION: CAR-T CELLS TARGETING CD19 AND CD22

TABLE 82: CLINICAL TRIALS DESCRIPTION: HUMNC2-CAR44

TABLE 83: GENERAL DESCRIPTION: HUMNC2-CAR44 CAR-T CELLS

TABLE 84: GENERAL DESCRIPTION: CD19-CART

TABLE 85: CLINICAL TRIALS DESCRIPTION: MB 106

TABLE 86: GENERAL DESCRIPTION: MB-106

TABLE 87: CLINICAL TRIALS DESCRIPTION: CTX110

TABLE 88: GENERAL DESCRIPTION: CTX110

TABLE 89: CLINICAL TRIALS DESCRIPTION: WU-CART-007

TABLE 90: GENERAL DESCRIPTION: WU-CART-007

TABLE 91: CLINICAL TRIALS DESCRIPTION: GC012F

TABLE 92: GENERAL DESCRIPTION: GC012F

TABLE 93: CLINICAL TRIALS DESCRIPTION: C CAR 039

TABLE 94: GENERAL DESCRIPTION: C CAR 039

TABLE 95: CLINICAL TRIALS DESCRIPTION: VOR33

TABLE 96: GENERAL DESCRIPTION: VOR33

TABLE 97: CLINICAL TRIALS DESCRIPTION: BBT369

TABLE 98: GENERAL DESCRIPTION: BBT369

TABLE 99: CLINICAL TRIALS DESCRIPTION: UCART20X22

TABLE 100: GENERAL DESCRIPTION: UCART20X22

TABLE 101: CLINICAL TRIALS DESCRIPTION: NXC-201

TABLE 102: GENERAL DESCRIPTION: NXC-201

TABLE 103: CLINICAL TRIALS DESCRIPTION: IVS-3001

TABLE 104: GENERAL DESCRIPTION: IVS-3001

TABLE 105: CLINICAL TRIALS DESCRIPTION: IMPT-314

TABLE 106: GENERAL DESCRIPTION: IMPT-314

TABLE 107: CLINICAL TRIALS DESCRIPTION: CT120

TABLE 108: GENERAL DESCRIPTION: CT120

TABLE 109: CLINICAL TRIALS DESCRIPTION: CD22 CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY

TABLE 110: GENERAL DESCRIPTION: AIC100

TABLE 111: CLINICAL TRIALS DESCRIPTION: CD19 CAR-T CELLS

TABLE 112: GENERAL DESCRIPTION: CD19 CAR-T CELL THERAPY

TABLE 113: CLINICAL TRIALS DESCRIPTION: CD22 CAR T CELL THERAPY (CART22-65S)

TABLE 114: GENERAL DESCRIPTION: CART22 THERAPY

TABLE 115: GENERAL DESCRIPTION: KD-182 CAR T CELLS

TABLE 116: CLINICAL TRIALS DESCRIPTION: CRC01

TABLE 117: GENERAL DESCRIPTION: CRC01

TABLE 118: CLINICAL TRIALS DESCRIPTION: CT041

TABLE 119: GENERAL DESCRIPTION: CT041

TABLE 120: CLINICAL TRIALS DESCRIPTION: VCAR33

TABLE 121: GENERAL DESCRIPTION: VCAR33

TABLE 122: CLINICAL TRIALS DESCRIPTION: PBCAR0191

TABLE 123: GENERAL DESCRIPTION: PBCAR0191

TABLE 124: CLINICAL TRIALS DESCRIPTION: HUMANIZED CD19 CAR-T CELLS

TABLE 125: GENERAL DESCRIPTION: HUMANIZED CD19 CAR-T CELLS

TABLE 126: CLINICAL TRIALS DESCRIPTION: TBI-1501

TABLE 127: GENERAL DESCRIPTION: TBI-1501

TABLE 128: CLINICAL TRIALS DESCRIPTION: BNT211

TABLE 129: GENERAL DESCRIPTION: BNT211

TABLE 130: CLINICAL TRIALS DESCRIPTION: MB-CART19.1

TABLE 131: GENERAL DESCRIPTION: MB-CART19.1

TABLE 132: CLINICAL TRIALS DESCRIPTION: MB-CART20.1

TABLE 133: GENERAL DESCRIPTION: MB-CART20.1

TABLE 134: CLINICAL TRIALS DESCRIPTION: CD-7 CAR-T MOLECULE

TABLE 135: GENERAL DESCRIPTION: CD-7 CAR-T MOLECULE

TABLE 136: GENERAL DESCRIPTION: KD-025 CAR T CELLS

TABLE 137: CLINICAL TRIALS DESCRIPTION: IM19 CAR-T

TABLE 138: GENERAL DESCRIPTION: IM19 CAR-T

TABLE 139: CLINICAL TRIALS DESCRIPTION: IC9-CAR19 CELLS

TABLE 140: GENERAL DESCRIPTION: IC9-CAR19 CELLS

TABLE 141: CLINICAL TRIALS DESCRIPTION: KYV-101

TABLE 142: GENERAL DESCRIPTION: KYV-101

TABLE 143: CLINICAL TRIALS DESCRIPTION: UCART22

TABLE 144: GENERAL DESCRIPTION: UCART22

TABLE 145: CLINICAL TRIALS DESCRIPTION: HUMANIZED CD19 CAR-T CELLS

TABLE 146: GENERAL DESCRIPTION: HUMANIZED CD19 CAR-T CELLS

TABLE 147: CLINICAL TRIALS DESCRIPTION: CAR-GPC3 T CELLS (BOXR 1030)

TABLE 148: GENERAL DESCRIPTION: BOXR 1030 (CAR-GPC3 T CELLS)

TABLE 149: CLINICAL TRIALS DESCRIPTION: BEAM-201

TABLE 150: GENERAL DESCRIPTION: BEAM-201

TABLE 151: CLINICAL TRIALS DESCRIPTION: AT101

TABLE 152: GENERAL DESCRIPTION: AT101

TABLE 153: EARLY-STAGE PRODUCTS (PHASE I)

TABLE 154: CLINICAL TRIALS DESCRIPTION: CT103A

TABLE 155: GENERAL DESCRIPTION: CT 103A

TABLE 156: GENERAL DESCRIPTION: AUTO1/22

TABLE 157: CLINICAL TRIALS DESCRIPTION: IM21 CAR-T CELLS

TABLE 158: GENERAL DESCRIPTION: IM21 CAR-T

TABLE 159: CLINICAL TRIALS DESCRIPTION: CAR-GPC3

TABLE 160: GENERAL DESCRIPTION: CAR-GPC3

TABLE 161: CLINICAL TRIALS DESCRIPTION: JCAR 020

TABLE 162: GENERAL DESCRIPTION: JCAR020

TABLE 163: CLINICAL TRIALS DESCRIPTION:  CD19 ARMORED CAR

TABLE 164: GENERAL DESCRIPTION: CD19 ARMORED CAR

TABLE 165: CLINICAL TRIALS DESCRIPTION: ALLO-715

TABLE 166: GENERAL DESCRIPTION: ALLO-715

TABLE 167: CLINICAL TRIALS DESCRIPTION: PRGN-3005

TABLE 168: GENERAL DESCRIPTION: PRGN-3005

TABLE 169: CLINICAL TRIALS DESCRIPTION: XYF19 CAR-T CELL

TABLE 170: GENERAL DESCRIPTION: XYF19 CAR-T CELL

TABLE 171: CLINICAL TRIALS DESCRIPTION: WZTL-002

TABLE 172: GENERAL DESCRIPTION: WZTL-002

TABLE 173: GENERAL DESCRIPTION: TI 1007

TABLE 174: GENERAL DESCRIPTION: KUR-501

TABLE 175: GENERAL DESCRIPTION: KUR-502

TABLE 176: CLINICAL TRIALS DESCRIPTION: GC019F

TABLE 177: GENERAL DESCRIPTION: GC019F

TABLE 178: GENERAL DESCRIPTION: MB-104

TABLE 179: GENERAL DESCRIPTION: MB-105

TABLE 180: GENERAL DESCRIPTION: MB-101

TABLE 181: CLINICAL TRIALS DESCRIPTION: CTX120

TABLE 182: GENERAL DESCRIPTION: CTX120

TABLE 183: CLINICAL TRIALS DESCRIPTION: CTX130

TABLE 184: GENERAL DESCRIPTION: CTX130

TABLE 185: CLINICAL TRIALS DESCRIPTION:  BCMA TARGETED CAR-T CELLS

TABLE 186: GENERAL DESCRIPTION: BCMA TARGETED CAR-T CELLS

TABLE 187: CLINICAL TRIALS DESCRIPTION: CD19/BCMA TARGETED CAR-T CELLS

TABLE 188: GENERAL DESCRIPTION: CD19/BCMA TARGETED CAR-T CELLS

TABLE 189: CLINICAL TRIALS DESCRIPTION: CD4CAR

TABLE 190: GENERAL DESCRIPTION: CD4CAR

TABLE 191: CLINICAL TRIALS DESCRIPTION: FT819

TABLE 192: GENERAL DESCRIPTION: FT-819

TABLE 193: CLINICAL TRIALS DESCRIPTION: CB-010

TABLE 194: GENERAL DESCRIPTION: CB-010

TABLE 195: CLINICAL TRIALS DESCRIPTION: P-MUC1C-ALLO1

TABLE 196: GENERAL DESCRIPTION: P-MUC1C-ALLO1

TABLE 197: CLINICAL TRIALS DESCRIPTION: P-BCMA-ALLO1

TABLE 198: GENERAL DESCRIPTION: P-BCMA-ALLO1

TABLE 199: CLINICAL TRIALS DESCRIPTION: TAA06

TABLE 200: GENERAL DESCRIPTION: TAA06

TABLE 201: CLINICAL TRIALS DESCRIPTION: TAK-103

TABLE 202: GENERAL DESCRIPTION: TAK-103

TABLE 203: CLINICAL TRIALS DESCRIPTION:  STK-009 + SYNCAR-001

TABLE 204: GENERAL DESCRIPTION: STK-009 + SYNCAR-001

TABLE 205: CLINICAL TRIALS DESCRIPTION: P-CD19CD20-ALLO1

TABLE 206: GENERAL DESCRIPTION: P-CD19CD20-ALLO1

TABLE 207: CLINICAL TRIALS DESCRIPTION: NIB101

TABLE 208: GENERAL DESCRIPTION: NIB 101

TABLE 209: CLINICAL TRIALS DESCRIPTION: SC-DARIC33

TABLE 210: GENERAL DESCRIPTION: SC-DARIC33

TABLE 211: GENERAL DESCRIPTION: IMPT-514

TABLE 212: CLINICAL TRIALS DESCRIPTION: SYNKIR-110

TABLE 213: GENERAL DESCRIPTION: SYNKIR-110

TABLE 214: GENERAL DESCRIPTION: MT027

TABLE 215: CLINICAL TRIALS DESCRIPTION: CT125A

TABLE 216: GENERAL DESCRIPTION: CT 125A

TABLE 217: CLINICAL TRIALS DESCRIPTION: RD133

TABLE 218: GENERAL DESCRIPTION: RD 133

TABLE 219: CLINICAL TRIALS DESCRIPTION: CT0181

TABLE 220: GENERAL DESCRIPTION: CT0181

TABLE 221: GENERAL DESCRIPTION: CT0590

TABLE 222: CLINICAL TRIALS DESCRIPTION: CT048

TABLE 223: GENERAL DESCRIPTION: CT048

TABLE 224: GENERAL DESCRIPTION: CT071

TABLE 225: CLINICAL TRIALS DESCRIPTION: ACLX 001

TABLE 226: GENERAL DESCRIPTION: ACLX 001

TABLE 227: CLINICAL TRIALS DESCRIPTION: ACLX 002

TABLE 228: GENERAL DESCRIPTION: ACLX 002

TABLE 229: CLINICAL TRIALS DESCRIPTION: BMS-986393

TABLE 230: GENERAL DESCRIPTION: BMS-986393

TABLE 231: GENERAL DESCRIPTION: ANTI-BCMA CAR-T CELL

TABLE 232: CLINICAL TRIALS DESCRIPTION: P-PSMA-101

TABLE 233: GENERAL DESCRIPTION: P-PSMA-101

TABLE 234: CLINICAL TRIALS DESCRIPTION: NIB-102

TABLE 235: GENERAL DESCRIPTION: NIB-102

TABLE 236: CLINICAL TRIALS DESCRIPTION: UCARTCS1

TABLE 237: GENERAL DESCRIPTION: UCARTCS1

TABLE 238: CLINICAL TRIALS DESCRIPTION: UCART123

TABLE 239: GENERAL DESCRIPTION: UCART123

TABLE 240: CLINICAL TRIAL DESCRIPTION: GPC3 TARGETING CAR-T CELLS

TABLE 241: GENERAL DESCRIPTION: GPC3 TARGETING CAR-T CELLS

TABLE 242: CLINICAL TRIALS DESCRIPTION: MB-103

TABLE 243: GENERAL DESCRIPTION: MB-103

TABLE 244: CLINICAL TRIALS DESCRIPTION: TAK-940

TABLE 245: GENERAL DESCRIPTION: TAK-940

TABLE 246: CLINICAL TRIALS DESCRIPTION: ADI-001

TABLE 247: GENERAL DESCRIPTION: ADI-001

TABLE 248: GENERAL DESCRIPTION: GC027

TABLE 249: CLINICAL TRIALS DESCRIPTION: IOMAB-ACT PROGRAM

TABLE 250: GENERAL DESCRIPTION: IOMAB-ACT PROGRAM

TABLE 251: CLINICAL TRIALS DESCRIPTION: ALLO-316

TABLE 252: GENERAL DESCRIPTION: ALLO-316

TABLE 253: CLINICAL TRIALS DESCRIPTION: MCARH 109

TABLE 254: GENERAL DESCRIPTION: GPRC5D CAR T (MCARH 109)

TABLE 255: CLINICAL TRIALS DESCRIPTION: CLBR001 + SWI019

TABLE 256: GENERAL DESCRIPTION: CLBR001 + SWI019

TABLE 257: CLINICAL TRIALS DESCRIPTION: ANTI-CD20-CAR

TABLE 258: GENERAL DESCRIPTION: ANTI-CD20 CAR

TABLE 259: CLINICAL TRIALS DESCRIPTION: PRGN-3007

TABLE 260: GENERAL DESCRIPTION: PRGN-3007

TABLE 261: CLINICAL TRIALS DESCRIPTION: CB-011

TABLE 262: GENERAL DESCRIPTION: CB-011

TABLE 263: CLINICAL TRIALS DESCRIPTION: KD-496

TABLE 264: GENERAL DESCRIPTION: KD-496

TABLE 265: GENERAL DESCRIPTION: AUTO8

TABLE 266: CLINICAL TRIALS DESCRIPTION: HYQVIA

TABLE 267: GENERAL DESCRIPTION: FOLLICLE STIMULATING HORMONE RECEPTOR T-CELLS

TABLE 268: CLINICAL TRIALS DESCRIPTION: SENL_1904B

TABLE 269: GENERAL DESCRIPTION: SENL_1904B

TABLE 270: CLINICAL TRIALS DESCRIPTION: THISCART22

TABLE 271: GENERAL DESCRIPTION: THISCART22

TABLE 272: CLINICAL TRIALS DESCRIPTION: AIC100

TABLE 273: GENERAL DESCRIPTION: AIC100

TABLE 274: CLINICAL TRIALS DESCRIPTION: PRGN-3006

TABLE 275: GENERAL DESCRIPTION: PRGN-3006

TABLE 276: CLINICAL TRIALS DESCRIPTION: CD79B CAR-T CELL THERAPY

TABLE 277: GENERAL DESCRIPTION: CD79B CAR-T CELL THERAPY

TABLE 278: CLINICAL TRIALS DESCRIPTION: APRIL CAR-T CELLS

TABLE 279: GENERAL DESCRIPTION: APRIL CAR-T CELLS

TABLE 280: CLINICAL TRIALS DESCRIPTION: LMP1 CAR-T CELLS

TABLE 281: GENERAL DESCRIPTION: LMP1 CAR-T CELLS

TABLE 282: CLINICAL TRIALS DESCRIPTION: NKG2D CAR-T CELL THERAPY

TABLE 283: GENERAL DESCRIPTION: NKG2D CAR-T CELL THERAPY

TABLE 284: CLINICAL TRIALS DESCRIPTION: TT11X

TABLE 285: GENERAL DESCRIPTION: TT11X

TABLE 286: CLINICAL TRIALS DESCRIPTION: CD38 CAR T

TABLE 287: GENERAL DESCRIPTION: CD38 CAR T

TABLE 288: CLINICAL TRIALS DESCRIPTION: BCMA-CART CELLS

TABLE 289: GENERAL DESCRIPTION: BCMA-CART CELLS

TABLE 290: CLINICAL TRIALS DESCRIPTION: AUTOLOGOUS CHIMERIC ANTIGEN RECEPTOR T-CELL TRANSFUSING AGENT TARGETING CD22

TABLE 291: GENERAL DESCRIPTION: AUTOLOGOUS CHIMERIC ANTIGEN RECEPTOR T-CELL TRANSFUSING AGENT TARGETING CD22

TABLE 292: CLINICAL TRIALS DESCRIPTION: CART-EGFRVIII

TABLE 293: GENERAL DESCRIPTION: CART-EGFRVIII

TABLE 294: CLINICAL TRIALS DESCRIPTION: BCMA CART

TABLE 295: GENERAL DESCRIPTION: CART-BCMA

TABLE 296: CLINICAL TRIALS DESCRIPTION: CART-MESO

TABLE 297: GENERAL DESCRIPTION: CART-MESO

TABLE 298: CLINICAL TRIALS DESCRIPTION: MURINE CD19 CAR-T CELLS

TABLE 299: GENERAL DESCRIPTION: MURINE CD19 CAR-T CELLS

TABLE 300: CLINICAL TRIALS DESCRIPTION: CS1 TARGETED CAR-T CELLS

TABLE 301: GENERAL DESCRIPTION: CS1 TARGETED CAR-T CELLS

TABLE 302: CLINICAL TRIALS DESCRIPTION: IL3 CAR-T CELLS

TABLE 303: GENERAL DESCRIPTION: IL3 CAR-T CELLS

TABLE 304: CLINICAL TRIALS DESCRIPTION: CD70 CAR-T CELLS

TABLE 305: GENERAL DESCRIPTION: CD70 CAR-T CELLS

TABLE 306: CLINICAL TRIALS DESCRIPTION: CD19 CAR T-CELLS

TABLE 307: GENERAL DESCRIPTION: CD19 CAR-T CELLS

TABLE 308: CLINICAL TRIALS DESCRIPTION: ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELLS (KD-019 CAR-T)

TABLE 309: GENERAL DESCRIPTION: ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELLS (KD-019 CAR-T)

TABLE 310: GENERAL DESCRIPTION: CD20 CAR T CELLS

TABLE 311: CLINICAL TRIALS DESCRIPTION: ANTI CD19 CAR

TABLE 312: GENERAL DESCRIPTION: ANTI CD19 CART

TABLE 313: CLINICAL TRIALS DESCRIPTION: CLL1-CD33 CCAR T CELLS

TABLE 314: GENERAL DESCRIPTION: CLL1B-CD33B COMPOUND CAR

TABLE 315: CLINICAL TRIALS DESCRIPTION: CD19 CARVAC CELL THERAPY

TABLE 316: GENERAL DESCRIPTION: CD19 CARVAC CELL THERAPY

TABLE 317: CLINICAL TRIALS DESCRIPTION: BCMA-CD19 CCAR T CELLS THERAPY

TABLE 318: GENERAL DESCRIPTION: BCMA-CD19 CCAR T CELLS THERAPY

TABLE 319: CLINICAL TRIALS DESCRIPTION: ANTI-CD123 CAR T CELLS

TABLE 320: GENERAL DESCRIPTION: ANTI-CD123 CAR T CELLS

TABLE 321: CLINICAL TRIALS DESCRIPTION: ANTI-MESO CAR T CELLS

TABLE 322: GENERAL DESCRIPTION: ANTI-CD123 CAR T CELLS

TABLE 323: CLINICAL TRIALS DESCRIPTION: ANTI-CD19/BCMA CAR-T CELLS

TABLE 324: GENERAL DESCRIPTION: ANTI-CD19/BCMA CAR-T CELLS

TABLE 325: CLINICAL TRIALS DESCRIPTION: TRIPLEX + CAR-TS

TABLE 326: GENERAL DESCRIPTION: TRIPLEX + CAR-TS

TABLE 327: CLINICAL TRIALS DESCRIPTION: HER2/MESOTHELIN/LEWIS-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T CELL THERAPY

TABLE 328: GENERAL DESCRIPTION: HER2/MESOTHELIN/LEWIS-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T CELL THERAPY

TABLE 329: CLINICAL TRIALS DESCRIPTION: CD20/CD22 DUAL TARGETED CAR-T CELLS

TABLE 330: GENERAL DESCRIPTION: CD20/CD22 DUAL TARGETED CAR-T CELLS

TABLE 331: CLINICAL TRIALS DESCRIPTION: CC-97540

TABLE 332: GENERAL DESCRIPTION: CC-97540

TABLE 333: CLINICAL TRIALS DESCRIPTION: CT0180

TABLE 334: GENERAL DESCRIPTION: CT0180

TABLE 335: CLINICAL TRIALS DESCRIPTION: LYM-920

TABLE 336: GENERAL DESCRIPTION: LMY-920

TABLE 337: GENERAL DESCRIPTION: BP2301

TABLE 338: GENERAL DESCRIPTION: OXFORD BIOMEDICA

TABLE 339: CLINICAL TRIALS DESCRIPTION: CD19 2ND GENERATION CAR-T THERAPY

TABLE 340: GENERAL DESCRIPTION: CD19 2ND GENERATION CAR-T THERAPY

TABLE 341: IND-STAGE PRODUCTS

TABLE 342: PRECLINICAL-STAGE PRODUCTS

TABLE 343: DISCOVERY-STAGE PRODUCTS

TABLE 344: UNKNOWN-STAGE PRODUCTS

TABLE 345: INACTIVE-STAGE PRODUCTS

TABLE 346: LIST OF MERGERS & ACQUISITIONS

TABLE 347: LIST OF PARTNERSHIPS & AGREEMENTS

TABLE 348: LIST OF INVESTMENTS

LIST OF FIGURES 

FIGURE 1: SCHEMATIC REPRESENTATION OF CHIMERIC ANTIGEN RECEPTOR (CAR) STRUCTURE

FIGURE 2: GENERATIONS OF CAR-T CELLS

FIGURE 3: PRODUCTS IN VARIOUS PHASES

FIGURE 4: EVALUATION BY ROUTE OF ADMINISTRATION

FIGURE 5: EVALUATION BY STAGE AND ROUTE OF ADMINISTRATION

FIGURE 6: EVALUATION BY THERAPY AREA

FIGURE 7: EVALUATION BY STAGE AND THERAPY AREA

FIGURE 8: EVALUATION BY PRODUCT TYPE

FIGURE 9: EVALUATION BY STAGE AND PRODUCT TYPE

FIGURE 10: LATE-STAGE PRODUCTS (REGISTERED)

FIGURE 11: MID-STAGE PRODUCTS (PHASE II)

FIGURE 12: EARLY-STAGE PRODUCTS (PHASE I/II)

FIGURE 13: EARLY-STAGE PRODUCTS (PHASE I)

FIGURE 14: IND-STAGE PRODUCTS

FIGURE 15: PRECLINICAL-STAGE PRODUCTS

FIGURE 16: DISCOVERY-STAGE PRODUCTS

FIGURE 17: INACTIVE STAGE PRODUCTS

FAQ’s

FAQs

Currently, CAR-T therapy is primarily used to treat certain types of blood cancers, such as acute lymphoblastic leukemia (ALL) and certain types of non-Hodgkin lymphoma. Research is ongoing to expand its application to other cancers, including solid tumors.

CAR-T therapy can provide a targeted approach to cancer treatment, leading to significant tumor reduction or complete remission in some patients who have not responded to other treatments. It offers a new hope for patients with relapsed or refractory cancers.

The future of CAR-T therapy is promising, with ongoing research aimed at improving its effectiveness, reducing side effects, and expanding its use to other types of cancer. Advances in genetic engineering and immunotherapy continue to drive the evolution of CAR-T treatments.

Request Customization
Request Customization
Request free sample